[feed] Atom [feed] RSS 1.0 [feed] RSS 2.0

Patidar, A and Selvaraj, S and Chauhan, P and Guzman, CA and Ebenson, T and Sarkar , A and Chattopadhyay, D and Saha, B (2020) Peptidoglycan-treated tumor antigen-pulsed dendriticcells impart complete resistance against tumor rechallenge. Clinical Experimental Immunology. 2020 Sep;201(3):279-288. , 201 (3). pp. 279-288.

Full text not available from this repository. (Request a copy)

Abstract

Solid tumors elicit suppressive T cell responses which impair antigen-presenting cell (APC) functions. Such immune suppression results in uncontrolled tumor growth and mortality. Addressing APC dysfunction, dendritic cell (DC)-mediated anti-tumor vaccination was extensively investigated in both mice and humans. These studies never achieved full resistance to tumor relapse. Herein, we describe a repetitive RM-1 murine tumor rechallenge model for recurrence in humans. Using this newly developed model, we show that priming with tumor antigen-pulsed, Toll-like receptor (TLR)2 ligand-activated DCs elicits a host-protective anti-tumor immune response in C57BL/6 mice. Upon stimulation with the TLR2 ligand peptidoglycan (PGN), the tumor antigen-pulsed DCs induce complete resistance to repetitive tumor challenges. Intra-tumoral injection of PGN reduces tumor growth. The tumor resistance is accompanied by increased expression of interleukin (IL)-27, T-box transcription factor TBX21 (T-bet), IL-12, tumor necrosis factor (TNF)-α and interferon (IFN)-γ, along with heightened cytotoxic T lymphocyte (CTL) functions. Mice primed four times with PGN-stimulated tumor antigen-pulsed DCs remain entirely resistant to repeat challenges with RM-1 tumor cells, suggesting complete prevention of relapse and recurrence of tumor. Adoptive transfer of T cells from these mice, which were fully protected from RM-1 rechallenge, confers anti-tumor immunity to syngeneic naive recipient mice upon RM-1 challenge. These observations indicate that PGN-activated DCs induce robust host-protective anti-tumor T cells that completely resist tumor growth and recurrence.

Item Type: Article
Subjects: Infection and Immunity
Depositing User: Mr. Rameshwar Nema
Date Deposited: 22 Jan 2021 08:44
Last Modified: 22 Jan 2021 08:44
URI: http://nccs.sciencecentral.in/id/eprint/872

Actions (login required)

View Item View Item